Atopic Dermatitis Clinical Trial
Official title:
The Use of Probiotic Lactobacillus Rhamnosus GG for Treatment of Atopic Dermatitis in Children
Atopic dermatitis (AD) is a multifactorial, chronic inflammatory skin disorder that results
in areas of dry, itchy skin. AD affects up to 20% of children in Western societies and
represents a prevalent, burdensome, and psychologically important pediatric concern.
It often appears in infancy and may persist into adolescence and adulthood. This complex
disease is typified by defective skin barrier function with activation of abnormal
immunological and inflammatory pathways upon exposure to ubiquitous environmental allergens.
It often appears in infancy and may persist into adolescence and adulthood. This complex
disease is typified by defective skin barrier function with activation of abnormal
immunological and inflammatory pathways upon exposure to ubiquitous environmental allergens.
This complex disease is typified by defective skin barrier function with activation of
abnormal immunological and inflammatory pathways upon exposure to ubiquitous environmental
allergens. This phenomenon may be primarily related to mutations in important barrier
proteins, in the same fashion as filaggrin in the atopic skin, or may be secondary,
reflecting the intestinal mucosal damage caused by local hypersensitivity reactions to food
antigens or to microbial components as in inflammatory bowel disease. Conventional therapy
for AD consists of elimination of exacerbating factors, moisturizers to maintain skin
hydration, antihistamines to alleviate pruritus, topically applied corticosteroids, or
topical calcineurin inhibitors to control inflammation. Severe forms of atopic dermatitis may
need systemic corticosteroids, oral cyclosporine, and/or phototherapy.
Probiotics have been suggested as a novel treatment approach for atopic dermatitis. Specific
probiotics have been shown to normalize intestinal permeability, to counteract intestinal
immune dysfunction and to normalize gut dysbiosis. Hence, their clinical benefit may reside
in the control of gut inflammation induced by various intraluminal antigens and enhancement
of adaptive and especially innate immune responses.
Indeed, above and beyond balancing the gut microecology and promoting host immune defences,
specific probiotics might further aid in controlling the microbial colonization of the skin,
thereby reducing proneness to secondary infections which typically cause sustained symptoms.
However, there are conflicting evidence on the utility of selected probiotic strains for
atopic dermatitis, and major problems are due to dose and viability of strain used, duration
of treatment, study population.
The aim of this randomized, double-blind, placebo-controlled study is to evaluate the
efficacy of the most studied probiotic in the pediatric allergy field - Lactobacillus
rhamnosus GG (LGG) - in children affected by atopic dermatitis.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05018806 -
Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis
|
Phase 2 | |
| Terminated |
NCT03847389 -
Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis
|
Phase 1/Phase 2 | |
| Completed |
NCT04090229 -
A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis
|
Phase 1 | |
| Active, not recruiting |
NCT05388760 -
Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1)
|
Phase 2 | |
| Completed |
NCT05530707 -
Evaluation of Acceptability, Skin Barrier Restoration and Balance of Atopic Skin Using Moisturizer
|
N/A | |
| Completed |
NCT02595073 -
Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis
|
Phase 3 | |
| Recruiting |
NCT05509023 -
Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)
|
Phase 2 | |
| Recruiting |
NCT05048056 -
Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis
|
Phase 2 | |
| Completed |
NCT04598269 -
Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis
|
Phase 2 | |
| Recruiting |
NCT03936335 -
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
|
||
| Withdrawn |
NCT03089476 -
Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy
|
N/A | |
| Recruiting |
NCT05029895 -
A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacitinib in Adolescent Participants Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD)
|
||
| Terminated |
NCT03654755 -
Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
|
Phase 2 | |
| Completed |
NCT04556461 -
Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function
|
Phase 2 | |
| Recruiting |
NCT04818138 -
BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort
|
N/A | |
| Completed |
NCT03719742 -
A Clinical Study to Evaluate the Safety and Efficacy of a Baby Cleanser and a Moisturizer
|
N/A | |
| Completed |
NCT05375955 -
A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.
|
Phase 2 | |
| Completed |
NCT03441568 -
In-home Use Test of the New Modified Diprobase Formulation to Assess the Safety and Tolerability in Infants and Children Under Physician's Control
|
N/A | |
| Recruiting |
NCT06366932 -
Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models
|
Phase 4 | |
| Completed |
NCT03304470 -
A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis
|
Phase 2 |